Kornimate/medical-research-clean huggingface dataset:
impact of acute hospitalisation and resistance training on muscle architecture and physical performance in older adults

Conditions: Sarcopenia; Functional Decline; Muscle Architecture; Gait Speed; Ultrasound; Physical Performance; Resistance Training; Hospitalisation; Acutely Ill; Older Adults

Summary: sarcopenia characterised by loss of muscle mass, muscle strength and physical performance burdens many older adults since the condition is related to functional decline. periods of inactivity such as during hospitalisation leads to further functional decline. it has been reported that the loss of muscle mass associated with sarcopenia not only entails a decrease in muscle mass but also changes in muscle architecture. knowledge on changes in muscle architecture is essential since it is one of the most important determinants on muscle strength and thus physical performance. the main objective of this study is to investigate changes in muscle architecture and physical performance during acute hospitalisation and after discharge in older adults and subsequently the effectiveness of resistance training of the lower limb during acute hospitalisation. if successful, our study could have a great impact on the individual, as well as societal level, due to a better understanding of the factors related to sarcopenia and the prevention of functional decline as a result of hospitalisation.


Eligibility criteria:
inclusion criteria: * ≥65 years of age * able to ambulate before hospitalization (with/without assistance) * able to communicate with the research team * expected length of stay ≥2 days * residing on funen exclusion criteria: * able to ambulate without assistance during current hospitalization * known severe dementia * positive confusion and assessment method score * patients who have received less than 3 resistance training sessions at discharge * terminal illness * recent major surgery or lower extremity bone fracture in the last 3 months * conditions contradicting use of robert(unstable vertebral-, pelvic, or lower extremity fractures * high intracranial pressure * pressure ulcers or risk of developing pressure ulcers due to fragile skin * patients with medical instability) * metastases at femur hip * deemed not suitable for resistance training sessions with the robot by the healthcare professional.
a retrospective study of neural network model to dynamically quantificate the severity in covid-19 disease

Conditions: COVID-19 Disease

Summary: the research aim to collect large samples of covid-19 disease patients with clinical symptoms, laboratory and imaging examination data. screening the biological indicators which are related to the occurrence of severe diseases. then, investigators using artificial intelligence (ai) technology deep learning method to find a prediction model that can dynamically quantify covid-19 disease severity.


Eligibility criteria:
inclusion criteria: * patients of covid-19 disease confirmed by virus nucleic acid rt-pcr and ct exclusion criteria: * unconfirmed suspected cases * patients during pregnancy and lactation * incomplete clinical data * inestigators considered patients ineligible for the trial
clinical study of moisture sensor dressing used for exuding wounds

Conditions: Exuding Wounds; Ulcer, Leg; Wound

Summary: observational prospective study of the clinical use of a wound dressing with a moisture sensor for use on exuding wounds.

the pmcf study will be performed as a prospective and open study of a wound dressing with a moisture sensor on exuding wounds. using drymax sensor and the display indication - advisory only - might influence the clinician's workflow and the patient's engagement in their care. the pmcf study aims to study the use of the sensor in the clinical procedure of dressing changes in one or more healthcare settings. to study how the new product is received, and how it is used in the workflow, related to its clinical performance. furthermore, the aim is to gather safety-related clinical data for common harms within exudate management.

Eligibility criteria:
inclusion criteria: * male or female, ≥18 years * presence of an exuding wound, according to the clinician's assessment * the wound is deemed suitable for treatment with drymax sensor * an appropriate dressing size is available to be used according to the size of the wound * the participant has given a written informed consent to participate in the study. exclusion criteria: * known pregnancy at the inclusion visit * known or suspected hypersensitivity to the drymax sensor or its components * mental inability, reluctance or language difficulties that cause difficulties in understanding the meaning of participating in the study * ongoing treatment with systemic antibiotics * illness or treatment of an indication other than the wound and which, according to the study personnel, can affect the wound treatment, the study, and/or the dressing.
evaluating breast cancer patients modesty during radiotherapy. a multicentric study

Conditions: Breast Cancer

Summary: patients affected by breast cancer undergo radiotherapy with bare chest and can therefore live the moments in which they undress in front of the radiation therapy technologists (rtts) in charge of their treatment as an extremely embarrassing one. furthermore, for some of these patients the relationship with their bodies has indeed changed since surgery (i.e. mutilations, scars), particularly for specific age or socio-economic groups. in this context, sub-standard care in maintaining modesty during breast cancer radiotherapy has been reported in literature, even if poorly studied. aim of this multicentric observational study is to describe how modesty is perceived by patients undergoing radiotherapy for breast cancer.


Eligibility criteria:
inclusion criteria * patients undergoing adjuvant radiotherapy for breast cancer * able to understand and sign informed consent exclusion criteria * patients with inadequate linguistic abilities and inability to express informed consent * patients denying informed consent * patients receiving palliative treatments * patients affected by major psychiatric disorders
familial hypercolerstremia as risk factor in stemi patient who underwent ppci

Conditions: Familial Hypercholesterolemia

Summary: famulial hypercolerstremia as risk factor

familial hypercolerestremia ad risk factor in stemi patient who underwent ppci

Eligibility criteria:
inclusion criteria: -all patient that underwent ppci exclusion criteria: * previous ischemic patient * patient with raised renal chemistry * patient for cabg
a mixed methods approach to the development and testing of the measure of drug self-management (meds)

Conditions: Diabetes; Hypertension

Summary: the study objective is to develop and test a measure of drug self-management for use in clinical settings among patients with hypertension and diabetes. while medication non-adherence is a highly recognized public health and patient safety concern, it is rarely assessed in a routine and consistent manner in clinical settings. with the aging of the us population and rising rates of chronic disease, an increasing number of adults are being prescribed multi-drug regimens that require greater self-management skills. despite the complexity of medication use, adherence has most commonly been measured as a limited set of behaviors (i.e., filling a prescription, taking doses). this emphasis has, over time, simplified how we think of prescription (rx) medication use and directed attention away from the full range of tasks associated with effective rx self-management. the field of health literacy research has deconstructed these tasks in considerable detail in recent years, and can offer insight into a more comprehensive measurement of patients' outpatient rx use. there is a clear need for a brief, yet inclusive, measure of adherence that can be used in clinical settings to routinely assess patients' use of complex rx regimens. such an assessment could be used to guide clinicians in addressing specific patient challenges to safe and appropriate medication use. in response to this need, our study proposes to develop a new assessment of medication self-management. this unique measure will utilize health literacy best practices to promote patient comprehension and ease-of-use; it will also be tailored to patients' actual regimens via electronic health record (ehr) data. finally, the tool will be available in both english and spanish to support use among diverse patient populations. our study aims are to: 1. develop and refine a measure of drug self-management (meds) prototype. 2. inform the content, structure and delivery of the meds through targeted discussions with patients, providers and information technology specialists. 3. test the reliability and validity of the meds among patients with diabetes and hypertension h1: the meds will strongly correlate with other self-report adherence measures.


Eligibility criteria:
inclusion criteria: * be ≥ 18 years old, * have a diagnosis of diabetes and hypertension, * be prescribed 3 or more drugs to treat these conditions, * speak english or spanish as their primary language, * have primary responsibility for administering their own medications, * be a registered unc patient. exclusion criteria: * severe, uncorrectable visual, hearing or cognitive impairments that would preclude study consent or participation.
evaluate the improving effects of visucomplex plus on quality of life in patients with amd

Conditions: AMD

Summary: this is an observational study in which patients affected by dry or wet amd will be enrolled, after signing the informed consent, according to eligibility criteria. patients, after signing the informed consent, will enter into a screening phase during which the concomitant medication, clinical history, physical examination (including smoking habits) will be checked and the inclusion/exclusion criteria will be assessed. then, at the time of baseline visit (v0) the eligible patients will be given visucomplex plus as monotherapy, 1 capsule daily after food, or for dry or wet amd patients under treatment with a stable dose of an anti-vegf drug, visucomplex plus, 1 capsule daily after food, upon physical decision. screening phase and the baseline visit (v0) could coincide.


Eligibility criteria:
inclusion criteria: * patient informed consent form (icf) signed * adult male and female irrespective of their age at the time of the signature of icf * patients affected by dry or wet amd irrespective of the disease severity and including newly diagnosed patients * patients with no treatment for amd or under treatment with stable doses of anti-vegf * willing to follow all study procedures, including attending all site visits, tests and examinations. exclusion criteria: * previously diagnosed optic neuropathies * decompensated diabetes or hypertension * retinal pathologies including hereditary forms * neurological, neurodegenerative or cerebrovascular conditions * patients with a significantly progressive opacity of lens in the previous 3 months prior to enrolment * surgical intervention for cataract in the previous 3 months prior to enrolment * previously diagnosed eye inflammatory conditions (uveitis) in the previous 3 months * refractive defects beyond the 5 spherical diopters, both positive and negative and over 3 cylindrical * any clinically significant history of serious digestive tract, liver, kidney, cardiovascular or hematological disease, * known drug and/or alcohol abuse * mental incapacity that precludes adequate understanding or cooperation * participation in another clinical study.
treatment of self harm scars with fraxel laser

Conditions: Self Harm

Summary: treatment of self harm scars with fractionated laser.

fractionated resurfacing lasers have been shown to be useful for scars including acne scars, burns scars and striae. we will treat self harm scars with 3 to 4 treatments using a "fraxel" fractionated laser. patients will be screened to ensure they are not actively engaged in self harm behaviors.

Eligibility criteria:
inclusion criteria: * self harm scars exclusion criteria: * active self harm behaviors
safety and efficacy study of exc 001 to improve the appearance of scars from prior breast surgery

Conditions: Reduction in Hypertrophic Skin Scarring

Summary: the study will investigate the efficacy of various doses and regimens of exc 001 in reducing skin scarring in subjects undergoing revision of scars from prior surgery. the study will also evaluate the safety and tolerability of exc 001 and placebo.


Eligibility criteria:
inclusion criteria: * subjects must have previous had breast surgery resulting in unacceptable scars. * subject has chosen to have breast scars revised. * subject must not be pregnant or lactating. exclusion criteria: * currently pregnant or pregnant during the 6 months, prior to inclusion in the study or lactating. * participation in another clinical trial within 30 days prior to the start of the study. * any other condition or prior therapy, which, in the opinion of the pi, would make the subject unsuitable for the study.

Keywords: skin scarring cicatrix breast scar
use of lung ultrasound to diagnose the etiology of respiratory failure in a picu.

Conditions: Pediatric Respiratory Diseases; Respiratory Failure

Summary: the purpose of this study is to determine the utility of point-of-care lung ultrasound (poc-lus) in identifying the etiology of acute respiratory failure in pediatric patients admitted to the pediatric intensive care unit.

respiratory failure is one of the most common conditions requiring admission to the pediatric intensive care unit (picu). as such, chest radiography has emerged as the most commonly utilized tool in the assessment of lung pathology despite evidence that it may not be the most accurate. since the seminal article by lichtenstein in 2008, lung ultrasound has emerged as an alternative to chest radiography in the assessment of critically ill adults. likewise, pediatric lung ultrasound has a growing body of research to support its use in commonly encountered lung pathology including pneumonia, asthma, bronchiolitis, acute chest syndrome, pleural effusions, and pneumothorax. despite the rapidly growing body evidence, there remains little literature to support its use the diagnosis and management of acute respiratory failure in the picu. the proposed study will evaluate whether point-of-care lung ultrasound is accurate in determining the etiology of acute respiratory failure on admission to the picu. specific aims include: * aim 1: to determine the sensitivity and specificity of point-of-care lung ultrasound examination in identifying the etiology of acute pediatric respiratory failure on admission to the picu. * aim 2: to determine the inter-observer reliability of point-of-care lung ultrasound examination findings in acute pediatric respiratory failure among trainee and expert sonographers. * aim 3: compare point-of-care lung ultrasound with chest radiography in the rate of detection of consolidation, interstitial edema, pneumothorax, and pleural effusion. * aim 4: describe the poc-lus findings in patients admitted to the picu with acute respiratory failure

Eligibility criteria:
inclusion criteria: * age greater than 37 weeks gestational age and less than 18 years * admitted to picu * clinical diagnosis of acute respiratory failure * requirement of non-invasive or invasive respiratory support (as defined by a clinical need for high flow nasal cannula \>1l/kg/min; ram cannula, nasal or full face mask delivered continuous positive airway pressure ventilation; ram cannula, nasal or full face mask delivered bi-level positive airway pressure ventilation; or invasive mechanical ventilation); requirement of supplemental oxygen with fio2 \> 0.35 while on high flow nasal cannula \ 90%; continuous nebulized therapy; or chronic use of home oxygen or ventilator support and any increase in home settings exclusion criteria: * hemodynamically unstable as defined by the initiation of or the need for increased vasopressor support within the previous 30 minutes * known chronic respiratory disease such as primary ciliary dyskinesia, cystic fibrosis, or congenital pulmonary malformations.
efficacy of inhaled aromatherapy on nausea and vomiting in hematological malignancies

Conditions: Hematological Malignancies

Summary: this project will optimise the management of chemotherapy-induced nausea and vomiting, with improvements in nausea and vomiting scores, quality of life and appetite expected in participants benefiting from the intervention. in all cases, the use of complementary methods is recommended and improves the management of people with cancer because they offer a person-centred approach.

the aim is to evaluate the efficacy of inhalation of a mixture of ginger and lemon essential oils (eo) versus placebo in addition to conventional antiemetic treatments on the intensity of chemo-induced nausea during the acute phase d1 (h24) of its onset in patients with c1 haematological malignancies. this multicentre study will be carried out in 5 establishments (haematology and oncology care sectors), which represents a very high potential for inclusion. in addition, the investigator expect a very high acceptance rate for this study. in fact, in the context of cinv, this care strategy may meet a patient's expectation of symptoms (nausea, vomiting) that they find difficult to manage. finally, it is known that patients in these care sectors are very keen on supportive care to improve their quality of life, so this is a potentially very interesting opportunity without any particular risk that is offered to participants in this study. a nurse and a doctor with a postgraduate diploma in aromatherapy are coordinating the team, with the support of a nurse trained in evidence-based practice research methodology. institutional procedures drawn up by the team at limoges university hospital describe the general procedure for using aromatherapy in a scientific and safe way, the protocols that can be used to describe the operating methods, the traceability of the manufacture of the mixtures and their administration, and the evaluation of their effectiveness. supporting documents, an information note and a monitoring sheet have been created and are being used.

Eligibility criteria:
inclusion criteria: * patients aged over 18 years, * chemo-naive patients at inclusion, * patients with haematological malignancies treated treated with chemotherapy, * patients physically and mentally able to use the aromastick, * patients who speak, read and write french, * patients who have given signed consent, * patients with social security cover. exclusion criteria: * asthmatic patients. * patients with anosmia. * patients allergic to eo, lemon or ginger. * patients who have already received aromatherapy to treat chemotherapy-induced nausea and vomiting, * patients practising herbal medicine or acupuncture, * pregnant and breast-feeding women, * patients under guardianship, tutorship or curatorship, * patients taking part in interventional studies involving antiemetic drugs or nutritional products, * patients who have already had cancer.
isometric hand grip training in obstructive sleep apnea (osa)

Conditions: Obstructive Sleep Apnea; Hypertension

Summary: obstructive sleep apnea (osa) is a common clinical condition, involving the development of arterial hypertension. a meta analysis study have shown that isometric hand grip training promotes blood pressure reduction. it is going to be conducted a clinical trail to determine the effects of hand grip training in osa patients to change the arterial hypertension.

background: obstructive sleep apnea (osa) is a common clinical condition, involving the development of arterial hypertension. meta analysis study have shown that isometric hand grip strength promotes blood pressure reduction, and its reduction is higher than that observed after aerobic training. objective: to analyze the effects of the isometric hand grip on blood pressure changes of patients with uncontrolled arterial hypertension with osa. methods: a randomized controlled trial involving 18 adults with osa and uncontrolled arterial hypertension of both sexes, randomized between control group (receive general guidelines) and hand grip group. 12 weeks of training with load equivalent to 30% of maximum voluntary capacity was performed. all participants will be submitted for evaluation of blood pressure (bp) central and brachial, pulse wave velocity, full polysomnography,before and after the study protocol (the change from the baseline at 12 weeks). expected results: the authors believe that hand grip training can change (reduce) blood pressure in patient with osa.

Eligibility criteria:
inclusion criteria: * osa diagnose based on polysomnography, * apnea-hypopnea index (ahi) \> 5, * arterial hypertension (systolic arterial pressure \> 140 mmhg or diastolic arterial pressure \> 90 mmhg) exclusion criteria: * other heart disease

Keywords: training hand grip exercise
investigating the use of regorafenib (stivarga®) in patients with metastatic colorectal cancer (mcrc) after failure of standard therapy

Conditions: Colorectal Neoplasm

Summary: the purpose of the study is to investigate the safety and effectiveness of stivarga in patients with metastatic colorectal carcinoma in routine use in germany. the study is purely observational, only data from routine treatment are to be collected. the treatment and treatment conditions are solely at discretion of the treating physician.


Eligibility criteria:
inclusion criteria:´ * male or female patients ≥ 18 years of age with metastatic crc for whom the decision has been taken by the investigator to treat with stivarga. * patients must have signed an informed consent form exclusion criteria:
antibody response to covid-19 vaccines in liver disease patients

Conditions: Chronic Liver Disease

Summary: currently the pfizer-biontech (mrna), sinovac (inactivated virus) and astrazeneca-oxford (adenovirus-vector) covid-19 vaccines are available for vaccination in hk. the american association of liver disease has recently published consensus statements for covid-19 vaccination in subjects with chronic liver disease (cld). patients with cld have dysregulated innate and adaptive immune response that may be associated with vaccine hypo-responsiveness and there are no data as to whether these patients may respond differently to the various vaccines. the humanity and health medical center (hhmc) is an active participant of the hk government covid-19 vaccination programs and patients with cld follow-up at hhmc will have access to the three different vaccines. the aim of this prospective study is to compare the antibody response of cld subjects to the pfizer-biontech (mrna), sinovac (inactivated virus) and astrazeneca-oxford (adenovirus-vector) covid-19 vaccines.


Eligibility criteria:
inclusion criteria: 1. subjects with chronic liver disease (cld) at the humanity and health medical group and eligible for the hk government vaccination programme; 2. able to understand and sign informed consent.; 3. underlying cld- defined as patients with chronic hepatitis b or c infections, liver cirrhosis, metabolic associated liver disease, hepatocellular carcinoma, alcoholic liver disease, autoimmune hepatitis, hemochrombtosis. exclusion criteria: 1. patients contraindicated for the covid -19 vaccination program due to uncontrolled co-morbitities; 2. past allergies to other vaccines; 3. pregnant subjects.